Sectors & IndustriesHealthcareDrug Manufacturers - General

Best General Drug Manufacturer Stocks to Buy Now (2022)

Top general drug manufacturer stocks in 2022 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

Horizon Therapeutics Public Co (NASDAQ:HZNP) is the top general drug manufacturer stock with a Zen Score of 73, which is 24 points higher than the general drug manufacturer industry average of 49. It passed 24 out of 33 due diligence checks and has strong fundamentals. Horizon Therapeutics Public Co has seen its stock lose -42.49% over the past year, underperforming other general drug manufacturer stocks by -39 percentage points.

Horizon Therapeutics Public Co has an average 1 year price target of $111.29, an upside of 76.73% from Horizon Therapeutics Public Co's current stock price of $62.97.

Horizon Therapeutics Public Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Horizon Therapeutics Public Co, 42.86% have issued a Strong Buy rating, 42.86% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amgen (NASDAQ:AMGN) is the second best general drug manufacturer stock with a Zen Score of 64, which is 15 points higher than the general drug manufacturer industry average of 49. It passed 24 out of 38 due diligence checks and has strong fundamentals. Amgen has seen its stock return 5.54% over the past year, overperforming other general drug manufacturer stocks by 9 percentage points.

Amgen has an average 1 year price target of $239.50, an upside of 5.52% from Amgen's current stock price of $226.97.

Amgen stock has a consensus Hold recommendation according to Wall Street analysts. Of the 14 analysts covering Amgen, 14.29% have issued a Strong Buy rating, 7.14% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 7.14% have issued a Strong Sell.

Pfizer (NYSE:PFE) is the third best general drug manufacturer stock with a Zen Score of 62, which is 13 points higher than the general drug manufacturer industry average of 49. It passed 23 out of 38 due diligence checks and has strong fundamentals. Pfizer has seen its stock lose -0.25% over the past year, overperforming other general drug manufacturer stocks by 3 percentage points.

Pfizer has an average 1 year price target of $56.17, an upside of 27.42% from Pfizer's current stock price of $44.08.

Pfizer stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Pfizer, 25% have issued a Strong Buy rating, 8.33% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

Gsk (NYSE:GSK) has an annual dividend yield of 6.42%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.69%. Gsk's dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 92.7% indicates that its high dividend yield might not be sustainable for the long-term.

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.68%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.69%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has not shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 67% indicates that its dividend yield is sustainable for the long-term.

Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.61%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.69%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 87.3% indicates that its dividend yield is sustainable for the long-term.

General drug manufacturer stocks were down -0.65% in the last day, and down -2.25% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

Grifols Sa (NASDAQ:GRFS) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 71, which is 22 points higher than the general drug manufacturer industry average of 49. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -54.23% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -51 percentage points.

Horizon Therapeutics Public Co (NASDAQ:HZNP) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Horizon Therapeutics Public Co has a valuation score of 71, which is 22 points higher than the general drug manufacturer industry average of 49. It passed 5 out of 7 valuation due diligence checks.

Horizon Therapeutics Public Co's stock has dropped -42.49% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -39 percentage points.

Gilead Sciences (NASDAQ:GILD) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gilead Sciences has a valuation score of 71, which is 22 points higher than the general drug manufacturer industry average of 49. It passed 5 out of 7 valuation due diligence checks.

Gilead Sciences's stock has dropped -12.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -9 percentage points.